

# Werner Hacke

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11664898/publications.pdf>

Version: 2024-02-01

291  
papers

68,931  
citations

2322

98  
h-index

632

257  
g-index

293  
all docs

293  
docs citations

293  
times ranked

31375  
citing authors

#	ARTICLE	IF	CITATIONS
1	A full year of the COVID-19 pandemic with two infection waves and its impact on ischemic stroke patient care in Germany. <i>European Journal of Neurology</i> , 2022, 29, 105-113.	3.3	23
2	Embotrap Extraction & Clot Evaluation & Lesion Evaluation for NeuroThrombectomy (EXCELLENT) Registry design and methods. <i>Journal of NeuroInterventional Surgery</i> , 2022, 14, 783-787.	3.3	3
3	Regional and national differences in stroke thrombolysis use and disparities in pricing, treatment availability, and coverage. <i>International Journal of Stroke</i> , 2022, 17, 990-996.	5.9	9
4	A look back at 35 years of neurological research and practice (NRP). <i>Neurological Research and Practice</i> , 2022, 4, 19.	2.0	0
5	GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke. <i>Future Cardiology</i> , 2021, 17, 19-38.	1.2	19
6	Surgical Decompression for Space-Occupying Hemispheric Infarction. <i>JAMA Neurology</i> , 2021, 78, 208.	9.0	52
7	Neurological research and practice: the first milestone has been reached. <i>Neurological Research and Practice</i> , 2021, 3, 3.	2.0	1
8	Analysis of Nationwide Stroke Patient Care in Times of COVID-19 Pandemic in Germany. <i>Stroke</i> , 2021, 52, 716-721.	2.0	62
9	Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry. <i>Blood Advances</i> , 2021, 5, 1081-1091.	5.2	30
10	Select wisely: the ethical challenge of defining large core with perfusion in the early time window. <i>Journal of NeuroInterventional Surgery</i> , 2021, 13, 497-499.	3.3	25
11	Acute ischemic stroke care in Germany – further progress from 2016 to 2019. <i>Neurological Research and Practice</i> , 2021, 3, 14.	2.0	22
12	Healthy Life-Year Costs of Treatment Speed From Arrival to Endovascular Thrombectomy in Patients With Ischemic Stroke. <i>JAMA Neurology</i> , 2021, 78, 709.	9.0	30
13	Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF. <i>American Heart Journal</i> , 2021, 236, 4-12.	2.7	4
14	Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke. <i>Stroke</i> , 2021, 52, 3258-3265.	2.0	5
15	Deep learning-based detection and segmentation of diffusion abnormalities in acute ischemic stroke. <i>Communications Medicine</i> , 2021, 1, .	4.2	24
16	Prior stroke and transient ischemic attack as risk factors for subsequent stroke in atrial fibrillation patients: A report from the GARFIELD-AF registry. <i>International Journal of Stroke</i> , 2020, 15, 308-317.	5.9	12
17	The impact of the DWI-FLAIR-mismatch in the ECASS-4 trial – A post hoc analysis. <i>European Stroke Journal</i> , 2020, 5, 370-373.	5.5	5
18	Challenging the Ischemic Core Concept in Acute Ischemic Stroke Imaging. <i>Stroke</i> , 2020, 51, 3147-3155.	2.0	122

#	ARTICLE	IF	CITATIONS
19	Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data. <i>Lancet, The</i> , 2020, 396, 1574-1584.	13.7	107
20	Neurological research and practice: the first year. <i>Neurological Research and Practice</i> , 2020, 2, 5.	2.0	4
21	Letter to the Editor regarding the article "Temporal trends in the accuracy of hospital diagnostic coding for identifying acute stroke: A population-based study"™ by Li L, Binney LE, Luengo-Fernandez R, Silver LW, Rothwell PM; on behalf of the Oxford Vascular Study. <i>European Stroke Journal</i> 2019 Oct 14. DOI: 10.1177/2396987319881017. <i>European Stroke Journal</i> , 2020, 5, 104-105.	5.5	2
22	Alteplase for Acute Ischemic Stroke in Patients Aged >80 Years. <i>Stroke</i> , 2020, 51, 2322-2331.	2.0	33
23	International Impact of <i>Stroke</i>. <i>Stroke</i> , 2020, 51, 1036-1039.	2.0	0
24	Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF. <i>Cardiology and Therapy</i> , 2019, 8, 283-295.	2.6	2
25	Preventing dementia by preventing stroke: The Berlin Manifesto. <i>Alzheimer's and Dementia</i> , 2019, 15, 961-984.	0.8	200
26	Age and Sex Differences in Ischemic Stroke Treatment in a Nationwide Analysis of 1.11 Million Hospitalized Cases. <i>Stroke</i> , 2019, 50, 3494-3502.	2.0	57
27	World Stroke Organization (WSO): Global Stroke Fact Sheet 2019. <i>International Journal of Stroke</i> , 2019, 14, 806-817.	5.9	249
28	Special topic section: linkages among cerebrovascular, cardiovascular, and cognitive disorders: Preventing dementia by preventing stroke: The Berlin Manifesto. <i>International Journal of Stroke</i> , 2019, , 174749301987191.	5.9	13
29	Antiplatelet Therapy After Noncardioembolic Stroke. <i>Stroke</i> , 2019, 50, 1812-1818.	2.0	25
30	Extending thrombolysis to 4.5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data. <i>Lancet, The</i> , 2019, 394, 139-147.	13.7	321
31	Distribution and evolution of acute interventional ischemic stroke treatment in Germany from 2010 to 2016. <i>Neurological Research and Practice</i> , 2019, 1, 4.	2.0	38
32	Priorities to reduce the burden of stroke in Latin American countries. <i>Lancet Neurology, The</i> , 2019, 18, 674-683.	10.2	102
33	Standards of Practice in Acute Ischemic Stroke Intervention International Recommendations. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 269-274.	0.5	3
34	Extending the time window for intravenous thrombolysis in acute ischemic stroke using magnetic resonance imaging-based patient selection. <i>International Journal of Stroke</i> , 2019, 14, 483-490.	5.9	82
35	Inpatient TIA and stroke care in adult patients in Germany - retrospective analysis of nationwide administrative data sets of 2011 to 2017. <i>Neurological Research and Practice</i> , 2019, 1, 39.	2.0	16
36	Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2019, 5, 145-152.	4.0	75

#	ARTICLE	IF	CITATIONS
37	Standards of practice in acute ischemic stroke intervention: International recommendations. <i>Interventional Neuroradiology</i> , 2019, 25, 31-37.	1.1	7
38	Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF. <i>International Journal of Cardiology</i> , 2018, 257, 78-83.	1.7	10
39	Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF. <i>American Heart Journal</i> , 2018, 200, 102-109.	2.7	6
40	HeadPoST. <i>Neurology</i> , 2018, 90, 885-889.	1.1	18
41	Recurrence of cervical artery dissection. <i>Neurology</i> , 2018, 90, e1372-e1378.	1.1	38
42	Professional guideline versus product label selection for treatment with IV thrombolysis: An analysis from SITS registry. <i>European Stroke Journal</i> , 2018, 3, 39-46.	5.5	7
43	Effect of General Anesthesia versus Conscious Sedation for Stroke Thrombectomy on Angiographic Workflow in a Randomized Trial: A Post Hoc Analysis of the SIESTA Trial. <i>Radiology</i> , 2018, 286, 1016-1021.	7.3	20
44	A New DAWN for Imaging-Based Selection in the Treatment of Acute Stroke. <i>New England Journal of Medicine</i> , 2018, 378, 81-83.	27.0	31
45	Standards of Practice in Acute Ischemic Stroke Intervention: International Recommendations. <i>American Journal of Neuroradiology</i> , 2018, 39, E112-E117.	2.4	19
46	Implementing the proclamation of stroke and potentially preventable dementias. <i>Journal of Clinical Hypertension</i> , 2018, 20, 1354-1359.	2.0	7
47	Response to the growing dementia burden must be broader. <i>Lancet Neurology</i> , The, 2018, 17, 934.	10.2	1
48	Implementing the Proclamation of Stroke and Potentially Preventable Dementias. <i>International Journal of Stroke</i> , 2018, 13, 780-786.	5.9	11
49	Standards of practice in acute ischemic stroke intervention: international recommendations. <i>Journal of NeuroInterventional Surgery</i> , 2018, 10, 1121-1126.	3.3	40
50	Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient-data meta-analysis of randomized trials. <i>International Journal of Stroke</i> , 2018, 13, 175-189.	5.9	36
51	Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. <i>European Heart Journal</i> , 2017, 38, ehw058.	2.2	203
52	Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin. <i>Circulation</i> , 2017, 135, 1001-1003.	1.6	30
53	Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial. <i>Thrombosis Research</i> , 2017, 156, 184-190.	1.7	11
54	Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	8

#	ARTICLE	IF	CITATIONS
55	Organizational Update. Stroke, 2017, 48, e157-e158.	2.0	1
56	Analyses of thrombi in acute ischemic stroke: A consensus statement on current knowledge and future directions. International Journal of Stroke, 2017, 12, 606-614.	5.9	128
57	Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients) Tj ETQq1 1 0.784314 rgBT /Overlock 1	1.6	74
58	Cost-Effectiveness of Solitaire Stent Retriever Thrombectomy for Acute Ischemic Stroke. Stroke, 2017, 48, 379-387.	2.0	115
59	Correlation of imaging and histopathology of thrombi in acute ischemic stroke with etiology and outcome: a systematic review. Journal of NeuroInterventional Surgery, 2017, 9, 529-534.	3.3	208
60	International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. American Heart Journal, 2017, 194, 132-140.	2.7	161
61	Predicting major bleeding in patients with noncardioembolic stroke on antiplatelets. Neurology, 2017, 89, 936-943.	1.1	34
62	Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.6	10
63	Organizational Update. Stroke, 2017, 48, e341-e342.	2.0	8
64	Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open, 2017, 7, e017157.	1.9	92
65	Diurnal Variation of Intravenous Thrombolysis Rates for Acute Ischemic Stroke and Associated Quality Performance Parameters. Frontiers in Neurology, 2017, 8, 341.	2.4	5
66	Managing reversal of direct oral anticoagulants in emergency situations. Thrombosis and Haemostasis, 2016, 116, 1003-1010.	3.4	39
67	Acute endovascular recanalization. Current Opinion in Neurology, 2016, 29, 30-36.	3.6	3
68	Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation" Circulation, 2016, 134, e7-8.	1.6	1
69	Acute Stroke Imaging Research Roadmap III Imaging Selection and Outcomes in Acute Stroke Reperfusion Clinical Trials. Stroke, 2016, 47, 1389-1398.	2.0	88
70	Restriction of therapy mainly explains lower thrombolysis rates in reduced stroke service levels. Neurology, 2016, 86, 1975-1983.	1.1	26
71	Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurology, The, 2016, 15, 566-573.	10.2	296
72	Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF. Europace, 2016, 18, 1135-1142.	1.7	31

#	ARTICLE	IF	CITATIONS
73	Early termination of THRILL, a prospective study of mechanical thrombectomy in patients with acute ischemic stroke ineligible for i.v. thrombolysis. Clinical Neuroradiology, 2016, 26, 499-500.	1.9	7
74	Ischemic core and hypoperfusion volumes predict infarct size in <scp>SWIFT PRIME</scp>. Annals of Neurology, 2016, 79, 76-89.	5.3	155
75	Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes. Stroke, 2016, 47, 2373-2379.	2.0	193
76	World Stroke Day 2016 â€œâ€œFace the facts: Stroke is treatableâ€œ International Journal of Stroke, 2016, 11, 844-845.	5.9	1
77	Access, timing and frequency of very early stroke rehabilitation â€œ insights from the Baden-Wuerttemberg stroke registry. BMC Neurology, 2016, 16, 222.	1.8	15
78	Effect of Conscious Sedation vs General Anesthesia on Early Neurological Improvement Among Patients With Ischemic Stroke Undergoing Endovascular Thrombectomy. JAMA - Journal of the American Medical Association, 2016, 316, 1986.	7.4	402
79	Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. Lancet Neurology, The, 2016, 15, 925-933.	10.2	187
80	Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. American Heart Journal, 2016, 179, 77-86.	2.7	51
81	Identification of imaging selection patterns in acute ischemic stroke patients and the influence on treatment and clinical trial enrollment decision making. International Journal of Stroke, 2016, 11, 180-190.	5.9	6
82	European Cooperative Acute Stroke Study-4: Extending the time for thrombolysis in emergency neurological deficits ECASS-4: EXTEND. International Journal of Stroke, 2016, 11, 260-267.	5.9	69
83	Mechanical thrombectomy in acute ischemic stroke: Consensus statement by ESO-Karolinska Stroke Update 2014/2015, supported by ESO, ESMINT, ESNR and EAN. International Journal of Stroke, 2016, 11, 134-147.	5.9	303
84	Decompressive Craniectomy for Infarction and Hemorrhage. , 2016, , 1200-1217.		0
85	Endovascular Therapy in Acute Ischemic Stroke. Stroke, 2016, 47, 548-553.	2.0	57
86	Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. Heart, 2016, 102, 1036-1043.	2.9	36
87	Cause of Death and Predictors of Allâ€œCause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. Journal of the American Heart Association, 2016, 5, e002197.	3.7	127
88	Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. Circulation, 2016, 133, 352-360.	1.6	141
89	Zerebrale DurchblutungsstÃ¶rungen: IschÃ¤mische Infarkte. Springer-Lehrbuch, 2016, , 179-240.	0.0	2
90	A collaborative sequential meta-analysis of individual patient data from randomized trials of endovascular therapy and tPA vs. tPA alone for acute ischemic stroke: <u>T</u><u>h</u><u>R</u><u>omb</u><u>E</u><u>ctomy</u><u>A</u><u>nd</u><u>t</u><u>PA</u> (TREAT) analysis: statistical analysis plan for a sequential meta-analysis performed within the VISTA-Endovascular collaboration. International Journal of Stroke, 2015, 10, 136-144.	5.9	13

#	ARTICLE	IF	CITATIONS
91	The Results of the Recent Thrombectomy Trials May Influence Stroke Care Delivery: Are You Ready?. International Journal of Stroke, 2015, 10, 646-650.	5.9	10
92	Thrombectomy in Patients Ineligible for iv tPA (THRILL). International Journal of Stroke, 2015, 10, 950-955.	5.9	15
93	Individual patient data meta-analysis of antiplatelet regimens after noncardioembolic stroke or TIA: rationale and design. International Journal of Stroke, 2015, 10, 145-150.	5.9	5
94	Intravenous Thrombolysis is Effective in Young Adults: Results from the Baden-Wuerttemberg Stroke Registry. Frontiers in Neurology, 2015, 6, 229.	2.4	8
95	Repeated Intra-Arterial Thrombectomy within 72 Hours in a Patient with a Clear Contraindication for Intravenous Thrombolysis. Case Reports in Vascular Medicine, 2015, 2015, 1-3.	0.2	12
96	Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. European Heart Journal, 2015, 36, 288-296.	2.2	266
97	State of Acute Endovascular Therapy. Stroke, 2015, 46, 1727-1734.	2.0	29
98	Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial. Journal of the American Heart Association, 2015, 4, e001349.	3.7	12
99	Evidence-Based Guidelines for the Management of Large Hemispheric Infarction. Neurocritical Care, 2015, 22, 146-164.	2.4	133
100	Circulatory and Respiratory Parameters during Acute Endovascular Stroke Therapy in Conscious Sedation or General Anesthesia. Journal of Stroke and Cerebrovascular Diseases, 2015, 24, 1244-1249.	1.6	28
101	Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). American Heart Journal, 2015, 170, 675-682.e8.	2.7	128
102	Endovascular stent thrombectomy: the new standard of care for large vessel ischaemic stroke. Lancet Neurology, The, 2015, 14, 846-854.	10.2	280
103	Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation. Europace, 2015, 17, 1007-1017.	1.7	46
104	Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke. New England Journal of Medicine, 2015, 372, 2285-2295.	27.0	4,255
105	Sedation vs. Intubation for Endovascular Stroke Treatment (SIESTA) – A Randomized Monocentric Trial. International Journal of Stroke, 2015, 10, 969-978.	5.9	80
106	Thrombolysis in acute stroke – Authors' reply. Lancet, The, 2015, 385, 1396.	13.7	5
107	Stroke Neurologists' Perspective on the New Endovascular Trials. Stroke, 2015, 46, 1447-1452.	2.0	116
108	Haemorrhage and hemicraniectomy. Current Opinion in Neurology, 2015, 28, 16-22.	3.6	19



#	ARTICLE	IF	CITATIONS
109	Acute Ischemic Stroke Therapy. JAMA Neurology, 2015, 72, 1405.	9.0	4
110	Letter by SchÄ¶nenberger et al Regarding Article, "Type of Anesthesia and Differences in Clinical Outcome After Intra-Arterial Treatment for Ischemic Stroke" Stroke, 2015, 46, e188.	2.0	1
111	Selection for Delayed Intravenous Alteplase Treatment Based on a Prognostic Score. International Journal of Stroke, 2015, 10, 90-94.	5.9	8
112	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2015, 17, 1467-1507.	1.7	951
113	The Heidelberg Bleeding Classification. Stroke, 2015, 46, 2981-2986.	2.0	755
114	Interventional Thrombectomy for Major Stroke "A Step in the Right Direction. New England Journal of Medicine, 2015, 372, 76-77.	27.0	32
115	Deep brain stimulation to reduce sexual drive. Journal of Psychiatry and Neuroscience, 2015, 40, 429-431.	2.4	17
116	ZerebrovaskulÄ¶re NotfÄ¶lle. , 2015, , 577-589.		0
117	ZerebrovaskulÄ¶re NotfÄ¶lle. , 2015, , 1-23.		0
118	Time to treatment with recombinant tissue plasminogen activator and outcome of stroke in clinical practice: retrospective analysis of hospital quality assurance data with comparison with results from randomised clinical trials. BMJ, The, 2014, 348, g3429-g3429.	6.0	81
119	Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. European Heart Journal, 2014, 35, 3377-3385.	2.2	154
120	Author reply. Europace, 2014, 16, 151-152.	1.7	2
121	Testing Devices for the Prevention and Treatment of Stroke and its Complications. International Journal of Stroke, 2014, 9, 683-695.	5.9	9
122	Management of Acute Stroke in Patients Taking Novel Oral Anticoagulants. International Journal of Stroke, 2014, 9, 627-632.	5.9	58
123	Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial. Heart Rhythm, 2014, 11, 925-932.	0.7	52
124	Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. European Heart Journal, 2014, 35, 1873-1880.	2.2	145
125	Hemicraniectomy in Older Patients with Extensive Middle-Cerebral-Artery Stroke. New England Journal of Medicine, 2014, 370, 1091-1100.	27.0	494
126	Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban. Stroke, 2014, 45, 1304-1312.	2.0	187



#	ARTICLE	IF	CITATIONS
127	Factors Associated With Major Bleeding Events. Journal of the American College of Cardiology, 2014, 63, 891-900.	2.8	212
128	Transcranial Laser Therapy in Acute Stroke Treatment. Stroke, 2014, 45, 3187-3193.	2.0	89
129	Remote or Extradural Intracerebral Hemorrhage—An Uncommon Complication of Stroke Thrombolysis. Stroke, 2014, 45, 1657-1663.	2.0	50
130	Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet, The, 2014, 384, 1929-1935.	13.7	1,971
131	Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. European Heart Journal, 2014, 35, 233-241.	2.2	81
132	Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial. Stroke, 2014, 45, 1739-1747.	2.0	142
133	Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation, 2014, 130, 138-146.	1.6	345
134	Pretreatment Blood—Brain Barrier Damage and Post-Treatment Intracranial Hemorrhage in Patients Receiving Intravenous Tissue-Type Plasminogen Activator. Stroke, 2014, 45, 2030-2035.	2.0	73
135	Good Times - Bad Times: My Story regarding Acute Stroke Treatment. Cerebrovascular Diseases, 2013, 36, 257-265.	1.7	0
136	Stroke Treatment Academic Industry Roundtable. Stroke, 2013, 44, 3596-3601.	2.0	23
137	Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation. Journal of the American College of Cardiology, 2013, 61, 651-658.	2.8	181
138	Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation. Circulation, 2013, 127, 224-232.	1.6	463
139	European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2013, 15, 625-651.	1.7	721
140	Outcomes After Cardioversion and Atrial Fibrillation Ablation in Patients Treated With Rivaroxaban and Warfarin in the ROCKET AF Trial. Journal of the American College of Cardiology, 2013, 61, 1998-2006.	2.8	240
141	Hemicraniectomy in the management of space-occupying ischemic stroke. Journal of Clinical Neuroscience, 2013, 20, 6-12.	1.5	18
142	Ultra-Early Intravenous Stroke Thrombolysis. Stroke, 2013, 44, 2913-2916.	2.0	23
143	Door-to-Needle Time and the Proportion of Patients Receiving Intravenous Thrombolysis in Acute Ischemic Stroke. Stroke, 2013, 44, 3249-3253.	2.0	40
144	Relationship Between Onset-to-Door Time and Door-to-Thrombolysis Time. Stroke, 2013, 44, 2808-2813.	2.0	35

#	ARTICLE	IF	CITATIONS
145	Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial. Journal of the American Heart Association, 2013, 2, e000067.	3.7	179
146	Recommendations on Angiographic Revascularization Grading Standards for Acute Ischemic Stroke. Stroke, 2013, 44, 2650-2663.	2.0	1,264
147	Endovascular Stroke Therapy. Stroke, 2013, 44, 1453-1455.	2.0	145
148	Efficacy and Safety of Rivaroxaban in Patients With Heart Failure and Nonvalvular Atrial Fibrillation. Circulation: Heart Failure, 2013, 6, 740-747.	3.9	102
149	End of Study Transition From Study Drug to Open-Label Vitamin K Antagonist Therapy. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 470-478.	2.2	39
150	(Here Comes that) Razors Edge Endovascular Stroke Therapy: The End, or Only the Beginning?. International Journal of Stroke, 2013, 8, 331-333.	5.9	9
151	EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. European Heart Journal, 2013, 34, 2094-2106.	2.2	356
152	Response to Letter Regarding Article, "Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R <sub>2</sub> CHADS <sub>2</sub> Index in the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition) Trial". Overlook 10 Tf 50	1.6	5
153	2013, 128, e172-3. Clinical Outcomes With Rivaroxaban in Patients Transitioned From Vitamin K Antagonist Therapy. Annals of Internal Medicine, 2013, 158, 861.	3.9	46
154	Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD Registry. PLoS ONE, 2013, 8, e63479.	2.5	375
155	Baroreflex Sensitivity to Predict Malignant Middle Cerebral Artery Infarction. Stroke, 2012, 43, 714-719.	2.0	32
156	Contemporary Outcome Measures in Acute Stroke Research. Stroke, 2012, 43, 1163-1170.	2.0	183
157	Improved Prediction of Poor Outcome After Thrombolysis Using Conservative Definitions of Symptomatic Hemorrhage. Stroke, 2012, 43, 240-242.	2.0	78
158	Oral Anticoagulants "A Frequent Challenge for the Emergency Management of Acute Ischemic Stroke. Cerebrovascular Diseases, 2012, 34, 411-418.	1.7	21
159	The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. European Heart Journal, 2012, 33, 2143-2150.	2.2	86
160	Selection of possible responders to thrombolytic therapy in acute ischemic stroke. Annals of the New York Academy of Sciences, 2012, 1268, 120-126.	3.8	1
161	International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). American Heart Journal, 2012, 163, 13-19.e1.	2.7	195
162	Lack of International Consensus on Ethical Aspects of Acute Stroke Trials. Journal of Stroke and Cerebrovascular Diseases, 2012, 21, 200-204.	1.6	7

#	ARTICLE	IF	CITATIONS
163	Commentary on a GWAS: HDAC9 and the risk for ischaemic stroke. BMC Medicine, 2012, 10, 70.	5.5	10
164	Fast-Track Intubation for Accelerated Interventional Stroke Treatment. Neurocritical Care, 2012, 17, 354-360.	2.4	19
165	Treatment of Acute Ischemic Stroke With Clot Retrieval Devices. Current Treatment Options in Cardiovascular Medicine, 2012, 14, 260-272.	0.9	15
166	Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurology, The, 2012, 11, 315-322.	10.2	310
167	Development, Expansion, and Use of a Stroke Clinical Trials Resource for Novel Exploratory Analyses. International Journal of Stroke, 2012, 7, 133-138.	5.9	75
168	The King is Dead (Warfarin): Direct Thrombin and Factor Xa Inhibitors: The Next Diadochian War?. International Journal of Stroke, 2012, 7, 139-141.	5.9	6
169	Ischämie des vorderen Kreislaufs. , 2012, , 369-390.		0
170	Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. New England Journal of Medicine, 2011, 365, 883-891.	27.0	8,006
171	Bleeding, mortality, and antiplatelet therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. American Heart Journal, 2011, 162, 98-105.e1.	2.7	41
172	Effect of Clopidogrel plus ASA vs. ASA Early after TIA and Ischaemic Stroke: A Substudy of the CHARISMA Trial. International Journal of Stroke, 2011, 6, 3-9.	5.9	73
173	DESTINY II: Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery II. International Journal of Stroke, 2011, 6, 79-86.	5.9	120
174	Frequency of Increased Blood Pressure Levels During Systemic Thrombolysis and Risk of Intracerebral Hemorrhage. Stroke, 2011, 42, 1702-1706.	2.0	22
175	Early Decompressive Hemicraniectomy in Older Patients With Nondominant Hemispheric Infarction Improves Outcome. Stroke, 2011, 42, 843-844.	2.0	19
176	Cerebral Infarction. , 2011, , 1426-1439.		0
177	Zerebrovaskuläre Notfälle. , 2011, , 655-667.		0
178	Critical Care of the Patient with Acute Stroke. , 2011, , 1008-1048.		0
179	Fast Point-of-Care Coagulometer Guided Reversal of Oral Anticoagulation at the Bedside Hastens Management of Acute Subdural Hemorrhage. Neurocritical Care, 2010, 13, 321-325.	2.4	19
180	Point-of-care reversal treatment in phenprocoumon-related intracerebral hemorrhage. Annals of Neurology, 2010, 67, 788-793.	5.3	33

#	ARTICLE	IF	CITATIONS
181	Intensive Care Management of Acute Stroke: Surgical Treatment. International Journal of Stroke, 2010, 5, 170-177.	5.9	12
182	Challenges for cerebrovascular disease. Frontiers in Neurology, 2010, 1, 3.	2.4	1
183	Response to Letter Regarding Article, "Smoking, Clopidogrel, and Mortality in Patients With Established Cardiovascular Disease". Circulation, 2010, 122, .	1.6	0
184	Bleeding Complications With Dual Antiplatelet Therapy Among Patients With Stable Vascular Disease or Risk Factors for Vascular Disease. Circulation, 2010, 121, 2575-2583.	1.6	218
185	Mismatch-Based Delayed Thrombolysis. Stroke, 2010, 41, e25-33.	2.0	154
186	Recanalization Devices Should Be Restricted to Clinical Trials. Stroke, 2010, 41, 191-193.	2.0	15
187	Effect of Clopidogrel on the Rate and Functional Severity of Stroke Among High Vascular Risk Patients. Stroke, 2010, 41, 1679-1683.	2.0	22
188	Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet, The, 2010, 375, 1695-1703.	13.7	1,871
189	European Stroke Facilities Survey: The German and Austrian Perspective. Cerebrovascular Diseases, 2009, 27, 138-145.	1.7	34
190	Decompressive Surgery for Severe Brain Edema. Journal of Intensive Care Medicine, 2009, 24, 168-178.	2.8	25
191	Smoking, Clopidogrel, and Mortality in Patients With Established Cardiovascular Disease. Circulation, 2009, 120, 2337-2344.	1.6	123
192	Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurology, The, 2009, 8, 141-150.	10.2	526
193	Stroke treatment with alteplase given 3-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurology, The, 2009, 8, 1095-1102.	10.2	303
194	Effectiveness and Safety of Transcranial Laser Therapy for Acute Ischemic Stroke. Stroke, 2009, 40, 1359-1364.	2.0	247
195	Point-of-Care International Normalized Ratio Testing Accelerates Thrombolysis in Patients With Acute Ischemic Stroke Using Oral Anticoagulants. Stroke, 2009, 40, 3547-3551.	2.0	80
196	Chapter 57 Thrombolytic therapy for acute stroke. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 94, 1155-1193.	1.8	11
197	Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet, The, 2008, 372, 1303-1309.	13.7	514
198	Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke. New England Journal of Medicine, 2008, 359, 1317-1329.	27.0	5,749

#	ARTICLE	IF	CITATIONS
199	Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Stroke in Patients with a History of Atrial Fibrillation: Subgroup Analysis of the CHARISMA Randomized Trial. <i>Cerebrovascular Diseases</i> , 2008, 25, 344-347.	1.7	26
200	Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stroke: Results of an International Phase III Trial. <i>Stroke</i> , 2008, 39, 87-99.	2.0	362
201	Predicting Long-Term Outcome After Acute Ischemic Stroke. <i>Stroke</i> , 2008, 39, 1821-1826.	2.0	242
202	Hemicraniectomy for space-occupying supratentorial ischemic stroke. <i>Future Neurology</i> , 2008, 3, 251-264.	0.5	9
203	Thrombolysis for acute stroke under antiplatelet therapy: safe enough to be beneficial?. <i>Nature Clinical Practice Neurology</i> , 2008, 4, 474-475.	2.5	25
204	Multivariable Analysis of Outcome Predictors and Adjustment of Main Outcome Results to Baseline Data Profile in Randomized Controlled Trials. <i>Stroke</i> , 2008, 39, 3316-3322.	2.0	397
205	Thrombolysis with alteplase for acute ischemic stroke: review of SITS-MOST and other Phase IV studies. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 783-788.	2.8	26
206	The Virtual International Stroke Trials Archive. <i>Stroke</i> , 2007, 38, 1905-1910.	2.0	101
207	Facilities Available in European Hospitals Treating Stroke Patients. <i>Stroke</i> , 2007, 38, 2985-2991.	2.0	141
208	An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. <i>European Heart Journal</i> , 2007, 28, 2200-2207.	2.2	68
209	Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery (DESTINY). <i>Stroke</i> , 2007, 38, 2518-2525.	2.0	784
210	Clinical review: Therapy for refractory intracranial hypertension in ischaemic stroke. <i>Critical Care</i> , 2007, 11, 231.	5.8	48
211	Shift Analysis Versus Dichotomization of the Modified Rankin Scale Outcome Scores in the NINDS and ECASS-II Trials. <i>Stroke</i> , 2007, 38, 3205-3212.	2.0	105
212	Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. <i>Lancet</i> , The, 2007, 369, 275-282.	13.7	2,527
213	Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial. <i>Journal of the American College of Cardiology</i> , 2007, 49, 1982-1988.	2.8	752
214	Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. <i>Lancet Neurology</i> , The, 2007, 6, 215-222.	10.2	1,580
215	Stroke managementâ€”The first 6 hours. <i>Nosotchu</i> , 2007, 29, 810-810.	0.1	0
216	MRI-based selection for thrombolysis beyond 3 hours. <i>Nosotchu</i> , 2007, 29, 573-577.	0.1	0

#	ARTICLE	IF	CITATIONS
217	Recommendations for the Management of Intracranial Haemorrhage â€œ Part I: Spontaneous Intracerebral Haemorrhage. Cerebrovascular Diseases, 2006, 22, 294-316.	1.7	393
218	MRI versus CT-based thrombolysis treatment within and beyond the 3 h time window after stroke onset: a cohort study. Lancet Neurology, The, 2006, 5, 661-667.	10.2	227
219	Can Multivariable Risk-Benefit Profiling Be Used to Select Treatment-Favorable Patients for Thrombolysis in Stroke in the 3- to 6-Hour Time Window?. Stroke, 2006, 37, 2963-2969.	2.0	26
220	The Strokeâ€™Thrombolytic Predictive Instrument. Stroke, 2006, 37, 2957-2962.	2.0	148
221	Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS). Stroke, 2006, 37, 1227-1231.	2.0	511
222	Outcome and Symptomatic Bleeding Complications of Intravenous Thrombolysis Within 6 Hours in MRI-Selected Stroke Patients. Stroke, 2006, 37, 852-858.	2.0	235
223	Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. New England Journal of Medicine, 2006, 354, 1706-1717.	27.0	2,582
224	Stroke: advances in therapy. Lancet Neurology, The, 2005, 4, 2.	10.2	5
225	Critical Care and Emergency Medicine Neurology in Stroke. Stroke, 2005, 36, 205-207.	2.0	12
226	The Desmoteplase in Acute Ischemic Stroke Trial (DIAS). Stroke, 2005, 36, 66-73.	2.0	980
227	Measuring Outcomes as a Function of Baseline Severity of Ischemic Stroke. Cerebrovascular Diseases, 2004, 18, 124-129.	1.7	80
228	Stroke Magnetic Resonance Imaging Is Accurate in Hyperacute Intracerebral Hemorrhage. Stroke, 2004, 35, 502-506.	2.0	409
229	Intravenöse Thrombolyse beim akuten Schlaganfall. Klinische Neuroradiologie, 2004, 14, 3-12.	0.9	4
230	Acute Treatment of Ischaemic Stroke. Cerebrovascular Diseases, 2004, 17, 30-46.	1.7	64
231	Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet, The, 2004, 363, 768-774.	13.7	2,316
232	An update on thrombolytic therapy for acute stroke. Current Opinion in Neurology, 2004, 17, 69-77.	3.6	51
233	Critical Care of the Patient with Acute Stroke. , 2004, , 987-1024.		0
234	Design of future acute-stroke treatment trials. Lancet Neurology, The, 2003, 2, 54-61.	10.2	24

#	ARTICLE	IF	CITATIONS
235	Imaging-Based Decision Making in Thrombolytic Therapy for Ischemic Stroke. Stroke, 2003, 34, 575-583.	2.0	287
236	Critical Care Neurology. , 2003, , 721-747.		0
237	Surgical Decompression of Patients With Large Middle Cerebral Artery Infarcts Is Effective. Stroke, 2003, 34, 2304-2305.	2.0	18
238	Brain Embolism. , 2003, , 373-391.		0
239	Acute Ischemic Stroke. , 2003, , 327-347.		0
240	Treatment of Acute Ischemic Stroke. Circulation, 2002, 106, 1736-1740.	1.6	32
241	Comparison of CT and CT Angiography Source Images With Diffusion-Weighted Imaging in Patients With Acute Stroke Within 6 Hours After Onset. Stroke, 2002, 33, 2426-2432.	2.0	241
242	Decompressive Surgery for Malignant Middle Cerebral Artery Territory Infarction. Practical Neurology, 2002, 2, 144-154.	1.1	3
243	Treatment of Acute Ischemic Stroke. Circulation, 2002, 106, 1563-1569.	1.6	42
244	Jugular Venous Oxygen Saturation Thresholds in Trauma Patients May Not Extrapolate to Ischemic Stroke Patients. Journal of Neurosurgical Anesthesiology, 2002, 14, 130-136.	1.2	24
245	From CURE to MATCH: ADP Receptor Antagonists as the Treatment of Choice for High-Risk Atherothrombotic Patients. Cerebrovascular Diseases, 2002, 13, 22-26.	1.7	33
246	THE VERY ACUTE STROKE TREATMENT: FIBRINOLYSIS AND AFTER. Clinical and Experimental Hypertension, 2002, 24, 595-602.	1.3	4
247	Thrombolysis for the Treatment of Acute Ischemic Stroke. Nosotchu, 2002, 24, 305-323.	0.1	0
248	Large and panhemispheric infarcts. , 2001, , 490-498.		4
249	Thrombolytic therapy for ischemic stroke—A review. Part II—Intra-arterial thrombolysis, vertebrobasilar stroke, phase IV trials, and stroke imaging. Critical Care Medicine, 2001, 29, 1819-1825.	0.9	88
250	Effect and Feasibility of Controlled Rewarming After Moderate Hypothermia in Stroke Patients With Malignant Infarction of the Middle Cerebral Artery. Stroke, 2001, 32, 2833-2835.	2.0	168
251	Thrombolytic therapy for ischemic stroke—A review. Part I—Intravenous thrombolysis. Critical Care Medicine, 2001, 29, 1812-1818.	0.9	76
252	Stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia. Annals of Neurology, 2001, 49, 460-469.	5.3	227



#	ARTICLE	IF	CITATIONS
253	Stroke. Annals of Emergency Medicine, 2001, 37, S137-S144.	0.6	17
254	Early Prediction of Irreversible Brain Damage after Ischemic Stroke at CT. Radiology, 2001, 219, 95-100.	7.3	325
255	Hemorrhagic Transformation of Ischemic Brain Tissue. Stroke, 2001, 32, 1330-1335.	2.0	508
256	Stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia. Annals of Neurology, 2001, 49, 460-469.	5.3	9
257	“Self-Fulfilling Prophecy” or Recognition Requires a Concept of Perception. Stroke, 2000, 31, 231-239.	2.0	2
258	Acute Treatment of Ischemic Stroke. Cerebrovascular Diseases, 2000, 10, 22-33.	1.7	85
259	Monitoring Intravenous Recombinant Tissue Plasminogen Activator Thrombolysis for Acute Ischemic Stroke With Diffusion and Perfusion MRI. Stroke, 2000, 31, 1318-1328.	2.0	195
260	Thrombolytic Properties of Leukocytes from Peripheral Blood in Healthy Subjects and in Patients with Acute Cerebral Ischemia. Thrombosis Research, 2000, 98, 29-37.	1.7	4
261	Bedside monitoring of cerebral blood flow in patients with acute hemispheric stroke. Critical Care Medicine, 2000, 28, 511-516.	0.9	45
262	A Standardized MRI Stroke Protocol. Stroke, 1999, 30, 765-768.	2.0	328
263	Herpes simplex virus encephalitis: chronic progressive cerebral MRI changes despite good clinical recovery and low viral load - an experimental mouse study. European Journal of Neurology, 1999, 6, 531-538.	3.3	33
264	Systemic lymphoma in patients with the initial diagnosis of primary central nervous system lymphoma: a report of two cases. Journal of Neurology, 1999, 246, 855-857.	3.6	0
265	ECASS-II: intravenous alteplase in acute ischaemic stroke. Lancet, The, 1999, 353, 67-68.	13.7	10
266	Early recanalisation in acute ischaemic stroke saves tissue at risk defined by MRI. Lancet, The, 1999, 353, 2036-2037.	13.7	270
267	Indomethacin for Brain Edema following Stroke. Cerebrovascular Diseases, 1999, 9, 248-250.	1.7	17
268	Controlled Safety Study of a Hemoglobin-Based Oxygen Carrier, DCLHb, in Acute Ischemic Stroke. Stroke, 1999, 30, 993-996.	2.0	256
269	Ultrastructural connective tissue abnormalities in patients with spontaneous cervicocerebral artery dissections. Annals of Neurology, 1998, 44, 281-285.	5.3	242
270	Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet, The, 1998, 352, 1245-1251.	13.7	3,216

#	ARTICLE	IF	CITATIONS
271	Role of CT Angiography in Patient Selection for Thrombolytic Therapy in Acute Hemispheric Stroke. Stroke, 1998, 29, 935-938.	2.0	210
272	Effects of Hypertonic Saline Hydroxyethyl Starch Solution and Mannitol in Patients With Increased Intracranial Pressure After Stroke. Stroke, 1998, 29, 1550-1555.	2.0	249
273	The ECASS 3-Hour Cohort. Cerebrovascular Diseases, 1998, 8, 198-203.	1.7	130
274	Dichotomized Efficacy End Points and Global End-Point Analysis Applied to the ECASS Intention-to-Treat Data Set. Stroke, 1998, 29, 2073-2075.	2.0	119
275	Hemicraniectomy with dural augmentation in medically uncontrollable hemispheric infarction. Neurosurgical Focus, 1997, 2, E7.	2.3	61
276	Neurocritical Care for Acute Ischemic Stroke. Neurosurgery Clinics of North America, 1997, 8, 271-282.	1.7	2
277	Intraventricular Brain-Derived Neurotrophic Factor Reduces Infarct Size after Focal Cerebral Ischemia in Rats. Journal of Cerebral Blood Flow and Metabolism, 1997, 17, 500-506.	4.3	314
278	Superoxide Dismutase Activity in Serum of Patients With Acute Cerebral Ischemic Injury. Stroke, 1997, 28, 2425-2428.	2.0	102
279	Infection-Associated Cervical Artery Dissection. Stroke, 1997, 28, 453-455.	2.0	60
280	Prognosis of Stroke Patients Requiring Mechanical Ventilation in a Neurological Critical Care Unit. Stroke, 1997, 28, 711-715.	2.0	152
281	Plasma Insulin-like Growth Factor I and IGF Binding Protein 3 Levels in Patients With Acute Cerebral Ischemic Injury. Stroke, 1997, 28, 1744-1748.	2.0	82
282	Spontaneous Resolution of a Large Spinal Epidural Hematoma: Case Report. Neurosurgery, 1996, 38, 816-818.	1.1	71
283	Hemicraniotomy in Space-Occupying Hemispheric Infarction: Useful Early Intervention or Desperate Activism?. Cerebrovascular Diseases, 1996, 6, 325-329.	1.7	43
284	'Malignant' Middle Cerebral Artery Territory Infarction. Archives of Neurology, 1996, 53, 309.	4.5	1,291
285	Current Trends in Therapy of Acute Ischaemic Stroke. Annals of Medicine, 1995, 27, 9-12.	3.8	2
286	Intravenous Thrombolysis With Recombinant Tissue Plasminogen Activator for Acute Hemispheric Stroke. JAMA - Journal of the American Medical Association, 1995, 274, 1017.	7.4	2,148
287	Decompressive surgery in space-occupying hemispheric infarction. Critical Care Medicine, 1995, 23, 1576-1587.	0.9	367
288	Decompressive Craniectomy for Cerebral Infarction. Stroke, 1995, 26, 259-264.	2.0	146

#	ARTICLE	IF	CITATIONS
289	Intensive Care of Acute Ischemic Stroke. Cerebrovascular Diseases, 1994, 4, 385-392.	1.7	36
290	Pure Motor Hemiparesis with Stable Somatosensory Evoked Potential Monitoring during Aneurysm Surgery. Neurosurgery, 1992, 31, 145-150.	1.1	30
291	Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Annals of Neurology, 1992, 32, 78-86.	5.3	970